BEGIN:VCALENDAR VERSION:2.0 PRODID:-//KESHO - ECPv6.15.20//NONSGML v1.0//EN CALSCALE:GREGORIAN METHOD:PUBLISH X-WR-CALNAME:KESHO X-ORIGINAL-URL:https://kesho-kenya.org X-WR-CALDESC:Events for KESHO REFRESH-INTERVAL;VALUE=DURATION:PT1H X-Robots-Tag:noindex X-PUBLISHED-TTL:PT1H BEGIN:VTIMEZONE TZID:Africa/Nairobi BEGIN:STANDARD TZOFFSETFROM:+0300 TZOFFSETTO:+0300 TZNAME:EAT DTSTART:20240101T000000 END:STANDARD END:VTIMEZONE BEGIN:VEVENT DTSTART;TZID=Africa/Nairobi:20260409T190000 DTEND;TZID=Africa/Nairobi:20260409T203000 DTSTAMP:20260424T204507 CREATED:20260407T093519Z LAST-MODIFIED:20260407T094833Z UID:41540-1775761200-1775766600@kesho-kenya.org SUMMARY:Treatment in Esophageal Cancer DESCRIPTION:THE ROLE OF MULTIMODAL Treatment in Esophageal Cancer \nDate: 9th April 2026 Time: 7 PM – 8:30 PM EAT \nMODERATOR \nDr. Omar Abdihamid Clinical Oncologist\, Garissa Regional Cancer Center | Vice President (EA)\, African Organisation for Research and Training in Cancer \nSPEAKERS \nDr. Juma Odoro Cardiothoracic and vascular surgeon\, JOOTRH Kisumu and Head of Unit Surgical Management of Esophageal Cancer \nDr. Rogers Mongare Consultant Clinical and Radiation Oncologist at Kenyatta National Hospital (KNH) The Role of Radiotherapy in the Management of Esophageal Cancer \nDr. Kevin Makori Consultant Clinical & Radiation Oncologist\, Homa Bay County Teaching and Referral Hospital | Clinical Trials Investigator\, Victoria Cancer Care & Research Center\, Nyamira Management of Metastatic Esophageal Cancer: Advances in Targeted and Combination Therapies \n \n CLICK TO REGISTER URL:https://kesho-kenya.org/event/treatment-in-esophageal-cancer/ CATEGORIES:CME 2026,Continuing Medical Education (CME) ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2026/04/WhatsApp-Image-2026-04-07-at-12.13.58-PM-e1775554431579.jpeg END:VEVENT BEGIN:VEVENT DTSTART;TZID=Africa/Nairobi:20260326T190000 DTEND;TZID=Africa/Nairobi:20260326T203000 DTSTAMP:20260424T204507 CREATED:20260324T112204Z LAST-MODIFIED:20260324T112936Z UID:41493-1774551600-1774557000@kesho-kenya.org SUMMARY:Optimizing Care in Colorectal Cancer DESCRIPTION:Date: 26th March 2026 \nTime: 7 PM – 8:30 PM EAT \nModerator \n\nDr. Andrew Odhiambo Medical Oncologist\, The Nairobi Hospital; Thematic Head & Program Director\, Medical Oncology\, UON\n\nSpeakers \nDr. Alex Muturi Colorectal Surgeon & Surgical Gastroenterologist\, Kenyatta University Teaching\, Research and Referral Hospital Locally Advanced Colon Cancer: Timing of Surgery Relative to Systemic Treatment \nDr. Caroline Tonio Medical Oncologist\, Clinical Research Fellow (Clinical Trials)\, The Christie NHS Foundation Trust\, UK & KUTRRH\, Kenya “Too Young for Colorectal Cancer?” Understanding the rise of EOCRC and its clinical impact. \n \n CLICK TO REGISTER URL:https://kesho-kenya.org/event/optimizing-care-in-colorectal-cancer/ CATEGORIES:CME 2026,Continuing Medical Education (CME) ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2026/03/WhatsApp-Image-2026-03-24-at-8.25.12-AM-e1774351309301.jpeg END:VEVENT BEGIN:VEVENT DTSTART;TZID=Africa/Nairobi:20260319T190000 DTEND;TZID=Africa/Nairobi:20260319T203000 DTSTAMP:20260424T204507 CREATED:20260318T112347Z LAST-MODIFIED:20260319T174535Z UID:41463-1773946800-1773952200@kesho-kenya.org SUMMARY:Renal Cell Carcinoma: Evidence-Based Integration of Surgery and Systemic Therapy DESCRIPTION:Evidence-Based Integration of Surgery and Systemic Therapy \nDate: 19th March 2026Time: 7 PM – 8:30 PM EAT \nMODERATORDr. Amina K. HabibMedical Oncologist\, Aga Khan University Hospital\, Nairobi \nDr. Carnjini YogeswaranConsultant Urological Surgeon | Kenyatta National HospitalTopic: Surgical Management of Locally Advanced and Oligometastatic Renal Cell Carcinoma \nDr. Douglas NyandikaPhysician and Medical Oncologist | The Nairobi HospitalTopic: Adjuvant and Metastatic Systemic Therapy in Renal Cell Carcinoma \nHighlights\nThis session examined the evolving management of renal cell carcinoma (RCC)\, focusing on how surgical and systemic approaches are increasingly integrated across the disease continuum. \nA central theme was the importance of risk-adapted\, multidisciplinary care\, particularly in settings where many patients are still present with advanced diseases. While improved imaging has increased incidental detection globally\, late-stage presentation remains common in Kenya\, shaping both prognosis and treatment strategy. \nFrom a surgical perspective\, nephron-sparing surgery remains standard for localized diseases\, while radical nephrectomy and complex resections play a critical role in locally advanced cases. In oligometastatic disease\, cytoreductive nephrectomy and metastasis-directed therapy may offer benefit in carefully selected patients\, particularly when integrated with systemic treatment strategies. \nSystemic therapy has expanded significantly\, with immune checkpoint inhibitors and targeted therapies now forming the backbone of treatment in advanced disease. Evidence from key trials demonstrates improved survival outcomes with combination regimens\, reinforcing a shift towards early and strategic use of systemic therapy\, particularly in metastatic and high-risk settings. \nIn the adjuvant setting\, therapies such as pembrolizumab have shown disease-free and overall survival benefit in selected high-risk patients\, highlighting the importance of post-surgical risk stratification and follow-up. \nHowever\, translating these advances into routine practice remains constrained by access\, cost and infrastructure. The discussion underscored the need for context-specific treatment pathways\, supported by multidisciplinary decision-making and strengthened health systems. \nAcross the session\, a consistent message emerged: optimal RCC outcomes depend on deliberate integration—of surgery\, systemic therapy and patient-centered decision-making. \nKey Takeaways \n\nRCC management requires integration of surgical and systemic therapies.\nLate-stage presentation remains a key challenge in many settings.\nNephron-sparing and radical surgery remain central to localized and advanced disease.\nImmunotherapy and targeted agents are transforming metastatic RCC outcomes.\nAdjuvant therapy is increasingly relevant in high-risk post-surgical patients.\nAccess\, cost and infrastructure continue to shape real-world implementation.\n\n  URL:https://kesho-kenya.org/event/renal-cell-carcinoma-2/ CATEGORIES:CME 2026,Continuing Medical Education (CME) ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2026/03/WhatsApp-Image-2026-03-18-at-10.33.25-AM-e1773833004541.jpeg END:VEVENT BEGIN:VEVENT DTSTART;TZID=Africa/Nairobi:20260312T190000 DTEND;TZID=Africa/Nairobi:20260312T203000 DTSTAMP:20260424T204507 CREATED:20260310T140249Z LAST-MODIFIED:20260319T174323Z UID:41385-1773342000-1773347400@kesho-kenya.org SUMMARY:Multiple Myeloma Care in Western Kenya DESCRIPTION:[vc_row][vc_column][vc_column_text css=””]Event Title: The Journey of Multiple Myeloma Care in Western Kenya \nAccreditation: CPD Accredited \n\nDate: 12th March 2026\nTime: 7 PM – 8:30 PM EAT\nOrganization: KESHO (Kenya Society of Haematology & Oncology)\n\nModerator:  \n\nDr. Matilda Ongondi: Consultant Physician and Clinical Haemato-Oncologist\, Kenyatta National Hospital.\n\nSpeakers \n\n\n\n\nDr. Teresa Lotodo: Senior Lecturer & Consultant Pathologist (AP/CP)Topic: Modern Diagnostic Paradigms in Multiple Myeloma: From Morphology to Molecular Risk Stratification \nDr. Rohini Radia: Consultant in BMT and HaematologyTopic: Contemporary Management of Multiple Myeloma: Sequencing\, Cellular Therapies and Risk-Adapted Strategies \nDr. Beatrice Melly: Clinical Haematologist\, Moi Teaching and Referral HospitalTopic: Building Sustainable Myeloma Care Pathways: Access\, Infrastructure and Multidisciplinary Integration \nHightlights\n\n\n\n\n\n\n\n\nThis session examined how multiple myeloma care is evolving within the Kenyan context\, bringing together perspectives on diagnostics\, treatment advances and system-level delivery. \nA central theme was the contrast between rapid global therapeutic progress and the realities of access and infrastructure in low- and middle-income settings. While survival outcomes have improved significantly with the introduction of proteasome inhibitors\, immunomodulatory agents and anti-CD38 therapies\, translating these gains into routine practice remains uneven. \nThe discussion highlighted the importance of accurate and timely diagnosis\, with a shift from morphology-based approaches towards molecular and cytogenetic risk stratification to guide treatment decisions. \nFrom a clinical perspective\, modern management is increasingly risk-adapted\, incorporating quadruplet induction regimens\, autologous stem cell transplantation and maintenance strategies. Emerging therapies\, including CAR-T cells and bispecific antibodies are redefining outcomes in relapsed disease\, though access remains limited in many settings. \nAt a systems level\, the AMPATH multiple myeloma program was presented as a model of how coordinated care can be built through partnerships\, integrating clinical care\, training and research within a learning health system. The approach emphasizes improving access\, strengthening diagnostic and treatment infrastructure\, and embedding multidisciplinary care pathways to support patients across the disease course. \nAcross the session\, a consistent message emerged: advancing myeloma care requires not only better therapies\, but systems capable of delivering them. \nKey Takeaways \n\nMyeloma outcomes are improving with novel and combination therapies.\nAccurate diagnosis and risk stratification are central to management.\nStandard care includes quadruplet induction\, ASCT and maintenance therapy.\nCAR-T and bispecific antibodies are reshaping relapsed disease care.\nSustainable progress depends on access\, infrastructure and integrated care models. URL:https://kesho-kenya.org/event/multiple-myeloma-care-in-western-kenya/ CATEGORIES:CME 2026,Conferences,Continuing Medical Education (CME) ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2026/03/WhatsApp-Image-2026-03-10-at-11.40.58-AM-1-e1773151318490.jpeg END:VEVENT BEGIN:VEVENT DTSTART;TZID=Africa/Nairobi:20260305T190000 DTEND;TZID=Africa/Nairobi:20260305T203000 DTSTAMP:20260424T204507 CREATED:20260303T081324Z LAST-MODIFIED:20260303T083141Z UID:41277-1772737200-1772742600@kesho-kenya.org SUMMARY:Women in Oncology DESCRIPTION:[vc_row][vc_column][vc_column_text css=””] \nWomen in Oncology this International Women’s Day! \nJoin us for a powerful CPD Accredited webinar hosted by KESHO — Kenya Society of Haematology & Oncology \nDate: 5th March 2026 \nTime: 7:00 PM – 8:30 PM EAT \nModerator: \n\nDr. Gladwell Kiarie — Medical Oncologist\, The Nairobi Hospital\n\nSpeakers: \n\nProf. Verna Vanderpuye\n\nSenior Consultant Clinical Oncologist & Deputy Director\, National Centre of Radiotherapy\, Oncology and Nuclear Medicine\, Korle-bu Teaching Hospital\, Accra\, Ghana Topic: Legacy and Leadership: Mentorship from Women Advancing Oncology in Africa \n\nDr. Chemtai Mungo\n\nAssistant Professor of Obstetrics and Gynaecology & Physician-Scientist\, University of North Carolina at Chapel Hill Topic: Purpose-Driven Careers: Global Health\, Research and Women’s Impact in Oncology \n\nDr. Anne Mwirigi\n\nConsultant Haematologist and Assistant Professor\, Aga Khan University Hospital Topic: Growing in Specialised Oncology: Lessons in Haematology \n\nProf. Nazik Hammad\n\nProfessor of Medical Oncology\, Saint Michael’s Hospital and University of Toronto Topic: Building Impactful Careers in Global Oncology: Mentorship\, Leadership and Equity in Cancer Care[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column][vc_btn title=”CLICK TO REGISTER” color=”danger” css=”” link=”url:https%3A%2F%2Fus02web.zoom.us%2Fwebinar%2Fregister%2FWN_2lIM-Q1-Rm6JSxlo9b0jmQ”][/vc_column][/vc_row] URL:https://kesho-kenya.org/event/women-in-oncology-2/ CATEGORIES:CME 2026,Continuing Medical Education (CME) ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2026/03/WhatsApp-Image-2026-03-03-at-8.06.46-AM-e1772525890478.jpeg END:VEVENT BEGIN:VEVENT DTSTART;TZID=Africa/Nairobi:20260226T190000 DTEND;TZID=Africa/Nairobi:20260226T203000 DTSTAMP:20260424T204507 CREATED:20260223T194335Z LAST-MODIFIED:20260319T173215Z UID:41036-1772132400-1772137800@kesho-kenya.org SUMMARY:Precision Pathways in Lymphoma DESCRIPTION:[vc_row][vc_column][vc_column_text css=””] \nDate: 26th February 2026Time: 7:00 PM – 8:30 PM (EAT) \n\nSpeakers \nModeratorDr Anne MwirigiConsultant Haematologist & Assistant Professor\, AKUH \nDr Rohini RadiaConsultant in BMT and Haematology\, Nairobi West HospitalStrategic Alignment in Lymphoma: From Precise Diagnosis to Clinical Excellence \nDr Jonathan WawireConsultant Anatomic Pathologist & Assistant Professor\, AKUHLymphoma Diagnostic Algorithm in Routine Practice \nHighlights\nThis session explored how lymphoma care is increasingly shaped by the alignment between diagnostic precision and therapeutic decision-making\, particularly in settings where access to advanced diagnostics remains variable. \nA central theme was the shift from morphology-led classification alone to a multi-parameter diagnostic approach\, integrating clinical context\, histopathology\, immunophenotyping and where available\, molecular profiling. As emphasized during the discussion\, classification is no longer purely descriptive: it directly determines treatment pathways\, prognosis and eligibility for emerging therapies. \nDr. Wawire outlined a structured diagnostic framework anchored on architecture\, cytology and clonality\, with morphology guiding the initial pathway and targeted immunohistochemistry refining classification. In routine practice\, a focused IHC panel (CD20\, CD3\, CD5\, CD10\, Cyclin D1) remains sufficient to classify most lymphomas and support timely clinical decisions. \nImportantly\, the session addressed the practical realities of diagnostic limitations. The distinction between “Not Otherwise Specified (NOS)” and “Not Further Classified (NFC)” was highlighted as a clinically responsible approach where molecular testing is unavailable maintaining transparency while ensuring patients are still appropriately managed. \nBuilding on this\, Dr. Radia emphasized that improved outcomes depend on early alignment between diagnostics\, treatment selection and delivery systems. In practice\, delays in diagnostic workflows or limited access to molecular testing can directly influence treatment choices and patient outcomes making coordination across pathology\, oncology and imaging essential. \nAs treatment options expand\, from immunochemotherapy to targeted agents\, CAR-T therapies and bispecific antibodies\, the need for early risk stratification and timely decision-making becomes even more critical\, particularly in balancing efficacy\, cost and access within real-world settings. \nAcross the case discussions\, a consistent message emerged: the quality and timeliness of diagnosis remain central to achieving better outcomes in lymphoma care. \nKey takeaways: \n\nLymphoma classification now relies on integrated clinical\, morphological and molecular assessment.\nFocused IHC panels remain highly effective in routine and resource-limited settings.\n“NFC” supports safe\, transparent reporting when advanced testing is unavailable.\nDiagnostic delays and access gaps can directly impact treatment decisions.\nEarly alignment across disciplines is essential to optimize outcomes. URL:https://kesho-kenya.org/event/precision-pathways-in-lymphoma/ CATEGORIES:CME 2026,Continuing Medical Education (CME) ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2026/02/WhatsApp-Image-2026-02-23-at-10.02.59-PM-e1771875762948.jpeg END:VEVENT BEGIN:VEVENT DTSTART;TZID=Africa/Nairobi:20260219T190000 DTEND;TZID=Africa/Nairobi:20260219T203000 DTSTAMP:20260424T204507 CREATED:20260218T181534Z LAST-MODIFIED:20260407T102753Z UID:40973-1771527600-1771533000@kesho-kenya.org SUMMARY:Management of Biliary and Gall Bladder Tumours DESCRIPTION:SUMMARY \nAdvances in the Multidisciplinary Management of Biliary and Gallbladder Tumours \nSpeakers: Prof. Elly Ogutu\, Dr. Mohan Ramchandani\, Dr. Kausik Bhattacharya\, Dr. M. Vamshi Krishna \nDate: 19 February 2026 \nThis session examined the management of biliary and gallbladder tumours through a multidisciplinary lens\, highlighting the importance of coordinated approaches across endoscopy\, surgery and oncology in improving patient outcomes. \nA central theme was the role of accurate and timely diagnosis\, with particular emphasis on tissue acquisition and the contribution of advanced endoscopic techniques in guiding clinical decision-making. The discussion underscored how delays or limitations in diagnostic pathways can significantly influence treatment options and outcomes. \nThrough the KNH–UoN strategic training partnership and collaboration with the Asian Institute of Gastroenterology\, the session reflected the value of regional expertise and diaspora engagement in strengthening clinical capacity and expanding access to specialised skills. \nFrom a clinical perspective\, evolving therapeutic strategies—including advances in surgical techniques and radiation oncology—were highlighted as critical components of care\, particularly when integrated within a multidisciplinary framework that supports individualized treatment planning. \nAcross the session\, a consistent message emerged: improving outcomes in biliary and gallbladder cancers will depend on strengthening diagnostic pathways and ensuring coordinated\, multidisciplinary care across the patient journey. \nKey Takeaways \n\nEarly and accurate diagnosis remains central to effective management.\nAdvanced endoscopic techniques play a key role in tissue sampling and staging.\nMultidisciplinary coordination improves treatment planning and outcomes.\nRegional and diaspora collaboration strengthens clinical capacity.\nIntegration of surgical\, endoscopic and oncological care is essential. URL:https://kesho-kenya.org/event/management-of-biliary-and-gall-bladder-tumours/ CATEGORIES:CME 2026,Continuing Medical Education (CME) ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2026/02/WhatsApp-Image-2026-02-18-at-10.47.07-AM-e1771438592764.jpeg END:VEVENT BEGIN:VEVENT DTSTART;TZID=Africa/Nairobi:20260212T080000 DTEND;TZID=Africa/Nairobi:20260212T170000 DTSTAMP:20260424T204507 CREATED:20251222T170033Z LAST-MODIFIED:20260407T085208Z UID:40759-1770883200-1770915600@kesho-kenya.org SUMMARY:Environmental Risks of Cancer DESCRIPTION:Speakers: Dr. Mary Nyangasi\, Dr. David Githanga\, Dr. Carolina Espina\nDate: 12 February 2026 \nHighlights\nThis session examined cancer risk through an environmental and public health lens\, highlighting the extent to which cancer burden is shaped by modifiable exposures rather than biology alone. A central theme was the recognition that cancer is not only a clinical or genetic condition\, but also a social and environmental disease\, with a substantial proportion of cases linked to preventable risk factors. Global evidence suggests that up to 40% of cancers are attributable to modified exposures\, including environmental and occupational risks. Dr. Githanga outlined the biological mechanisms through which environmental exposures drive carcinogenesis\, including DNA damage\, chronic inflammation\, epigenetic dysregulation and impaired immune surveillance. These pathways act cumulatively over time\, often with long latency periods between exposure and disease manifestation. \nReal-world examples such as air pollution\, aflatoxin exposure and oncogenic infections illustrate how environmental context directly shapes cancer patterns\, particularly in low- and middle-income settings where exposure levels are higher and regulatory systems less robust. Building on this\, Dr. Nyangasi emphasized that a significant proportion of cancer burden is preventable\, with WHO frameworks highlighting the importance of population-level interventions targeting modifiable risk factors\, including environmental regulation\, vaccination and lifestyle-related risks. \nDr. Espina introduced the World Code Against Cancer framework\, which translates complex scientific evidence into clear\, actionable recommendations for individuals\, health systems and policymakers. The framework underscores the importance of moving beyond individual behavior change towards coordinated\, multi-sectoral prevention strategies. Across the session\, a consistent message emerged: meaningful reductions in cancer burden will depend on shifting upstream towards prevention\, regulation and system-level action \nKey Takeaways \n\nA substantial proportion of cancers are linked to modifiable environmental and behavioral exposures.\nEnvironmental carcinogenesis occurs through multi-pathway biological mechanisms over time.\nExposure to risk is uneven and shaped by social and economic conditions.\nPopulation-level interventions have greater impact than individual behavior change alone.\nEffective cancer control requires alignment between clinical practice\, public health and policy. URL:https://kesho-kenya.org/event/environmental-risks-of-cancer/ CATEGORIES:CME 2026,Continuing Medical Education (CME) ATTACH;FMTTYPE=image/png:https://kesho-kenya.org/wp-content/uploads/2025/12/Environmental-Risks-of-Cancer.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=Africa/Nairobi:20260205T190000 DTEND;TZID=Africa/Nairobi:20260205T203000 DTSTAMP:20260424T204507 CREATED:20260203T112643Z LAST-MODIFIED:20260319T172224Z UID:40841-1770318000-1770323400@kesho-kenya.org SUMMARY:World Cancer Day DESCRIPTION:[vc_row][vc_column][vc_column_text] \nWorld Cancer Day: \nUnited by Unique – The Kenyan Perspective \nDate: 5th February 2025Time: 7:00 PM – 8:30 PM (EAT) \nModerator \nDr. Gladwell KiarieMedical Oncologist\, The Nairobi Hospital \nSpeakers \nHon. Dr. Ouma OlugaPrincipal Secretary for the State Department for Medical Services\,Ministry of Health\, Kenya \nHon. Dr. James NyikalChairperson of the National Assembly Departmental Committee on Health\, Kenya \nDr. Mercy MwangangiChief Executive Officer\, Social Health Authority \nDr. Elias MellyChief Executive Officer\, National Cancer Institute\, Kenya \nDr. Ahmed OgwellPublic Health Expert\, CEO & President\, VillageReach \nPrisca GithukaVice-Chairperson & Advocacy Chair\,Kenyan Network of Cancer Organizations (KENCO) and Chairlady\,Cancer Survivors Association of Kenya \nHighlights\nThis session brought together clinical\, policy and advocacy voices to reflect on the current state of cancer care in Kenya\, with a focus on how systems\, leadership and lived experience intersect to shape outcomes. \nA central theme was the need to move beyond fragmented approaches towards coordinated\, patient-centered cancer control\, grounded in national priorities and responsive to the realities of care delivery. The discussion highlighted that improving outcomes requires not only clinical excellence\, but also alignment across policy\, financing and implementation. \nSpeakers emphasized the importance of strengthening health systems to support prevention\, early detection and access to treatment\, while addressing structural barriers that continue to limit equitable care. The role of national institutions\, policy frameworks and cross-sector collaboration emerged as critical in driving sustainable progress. \nPatient voice and lived experience were also highlighted as essential to shaping responsive and inclusive cancer care strategies\, ensuring that interventions reflect the needs and realities of those most affected. \nAcross the discussion\, a consistent message emerged: meaningful progress in cancer control will depend on alignment between policy\, practice and people. \nKey Takeaways \n\nEffective cancer control requires alignment across clinical care\, policy and implementation.\nStrengthening health systems is essential to improving access\, equity and outcomes.\nPrevention and early detection remain critical entry points for reducing burden.\nPatient voice and lived experience are key to responsive\, person-centered care.\nSustainable progress depends on multi-sector collaboration and leadership.\n\nWatch the full session here: \n \n Watch Video URL:https://kesho-kenya.org/event/world-cancer-day/ LOCATION:Virtual Event (Zoom)\, Kenya CATEGORIES:CME 2026,Continuing Medical Education (CME) ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2026/02/WhatsApp-Image-2026-02-03-at-2.30.14-PM-e1770118388259.jpeg END:VEVENT BEGIN:VEVENT DTSTART;TZID=Africa/Nairobi:20260131T080000 DTEND;TZID=Africa/Nairobi:20260131T170000 DTSTAMP:20260424T204507 CREATED:20251222T165602Z LAST-MODIFIED:20251223T153057Z UID:40755-1769846400-1769878800@kesho-kenya.org SUMMARY:HPV Vaccine Campaign/Outreach Screening DESCRIPTION: URL:https://kesho-kenya.org/event/hpv-vaccine-campaign-outreach-screening/ CATEGORIES:CME 2026,Continuing Medical Education (CME) END:VEVENT BEGIN:VEVENT DTSTART;TZID=Africa/Nairobi:20260122T190000 DTEND;TZID=Africa/Nairobi:20260122T203000 DTSTAMP:20260424T204507 CREATED:20251222T165215Z LAST-MODIFIED:20260319T171500Z UID:40753-1769108400-1769113800@kesho-kenya.org SUMMARY:Cervical Cancer Prevention and Control In Kenya DESCRIPTION:[vc_row][vc_column][vc_column_text css=””] \n(CPD Accredited) \nDate & Time: 22nd January 2026 7 PM – 8:30 PM (EAT) \n\nModerator: Dr. Benjamin Elly Odongo\nObstetrician/Gynecologist & Gynaecologic Oncologist\, Senior Lecturer & Chairman\, Department of Obstetrics & Gynaecology\, Kenyatta University School of Health Sciences\n\nSpeakers: \nProf. Lucy Muchiri\nAssociate Professor in the Department of Human Pathology\, University of Nairobi’s School of Medicine\nTopic: Overview of the WHO 90-70-90 cervical cancer elimination strategy and implications for pathology services \nProf. Omu Anzala Professor of Virology and Immunology\, Department of Medical Microbiology; Senior Research Scientist at KAVI – Institute of Clinical Research (KAVI – ICR)\, University of Nairobi\, Kenya\nTopic: HPV Vaccination in Kenya: Scientific Evidence\, Immunological Perspectives\, and Public Controversies \nDr. Richa Bansal Gynecological Oncologist and Robotic Surgeon\, Apollo Hospitals\, Navi Mumbai\, India\nTopic: Cervical Cancer Prevention and Advanced Treatment \nHighlights\nThis session examined cervical cancer through the lens of prevention\, highlighting it as one of the few cancers where elimination is both feasible and within reach. \nA central theme was the WHO 90-70-90 strategy\, which outlines a clear pathway to elimination through HPV vaccination\, screening and timely treatment. Achieving these targets could reduce cervical cancer incidence to below 4 cases per 100\,000 women\, effectively transforming it into a rare disease. \nThe discussion emphasized that cervical cancer is almost entirely driven by persistent HPV infection\, making it uniquely preventable through vaccination and early detection. Evidence shows that HPV vaccines are highly effective\, with strong and sustained protection against high-risk HPV types responsible for most cases. \nDespite this\, the burden remains disproportionately high in low- and middle-income settings\, including Kenya\, where gaps in screening coverage\, diagnostic capacity and referral pathways continue to limit early detection and timely treatment. \nThe role of pathology services emerged as critical\, forming the diagnostic backbone for screening programs and treatment decisions. Expanding HPV DNA testing\, strengthening laboratory systems and investing in workforce development were identified as key priorities for achieving national targets. \nAcross the session\, a consistent message emerged: cervical cancer is preventable and eliminating it will depend on scaling what already works. \nKey Takeaways \n\nCervical cancer is one of the few cancers where elimination is achievable.\nThe WHO 90-70-90 targets provide a clear\, evidence-based roadmap.\nHPV vaccination and screening are high-impact prevention strategies.\nStrengthening pathology and diagnostic capacity is essential to progress.\nClosing gaps in access and coverage is critical to achieving equitable outcomes. URL:https://kesho-kenya.org/event/cervical-cancer-prevention/ CATEGORIES:CME 2026,Continuing Medical Education (CME) ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2026/01/WhatsApp-Image-2026-01-20-at-9.44.15-AM-e1768910604384.jpeg END:VEVENT BEGIN:VEVENT DTSTART;TZID=Africa/Nairobi:20251222T080000 DTEND;TZID=Africa/Nairobi:20251222T170000 DTSTAMP:20260424T204507 CREATED:20251222T171421Z LAST-MODIFIED:20251223T152917Z UID:40765-1766390400-1766422800@kesho-kenya.org SUMMARY:Multiple Myeloma DESCRIPTION: URL:https://kesho-kenya.org/event/multiple-myeloma-2/ CATEGORIES:CME 2026,Continuing Medical Education (CME) END:VEVENT BEGIN:VEVENT DTSTART;TZID=Africa/Nairobi:20250625T190000 DTEND;TZID=Africa/Nairobi:20250625T203000 DTSTAMP:20260424T204507 CREATED:20251223T210004Z LAST-MODIFIED:20251223T210004Z UID:40823-1750878000-1750883400@kesho-kenya.org SUMMARY:Sickle Cell Disease DESCRIPTION: URL:https://kesho-kenya.org/event/sickle-cell-disease-3/ CATEGORIES:CME 2026,Continuing Medical Education (CME) END:VEVENT BEGIN:VEVENT DTSTART;TZID=Africa/Nairobi:20250618T190000 DTEND;TZID=Africa/Nairobi:20250618T203000 DTSTAMP:20260424T204507 CREATED:20251223T205914Z LAST-MODIFIED:20251223T205914Z UID:40821-1750273200-1750278600@kesho-kenya.org SUMMARY:Cancer and Nutrition DESCRIPTION: URL:https://kesho-kenya.org/event/cancer-and-nutrition/ CATEGORIES:CME 2026,Continuing Medical Education (CME) END:VEVENT BEGIN:VEVENT DTSTART;TZID=Africa/Nairobi:20250611T190000 DTEND;TZID=Africa/Nairobi:20250611T203000 DTSTAMP:20260424T204507 CREATED:20251223T205807Z LAST-MODIFIED:20251223T205807Z UID:40819-1749668400-1749673800@kesho-kenya.org SUMMARY:Palliative Care: Integrative Oncology DESCRIPTION: URL:https://kesho-kenya.org/event/palliative-care-integrative-oncology/ CATEGORIES:CME 2026,Continuing Medical Education (CME) END:VEVENT BEGIN:VEVENT DTSTART;TZID=Africa/Nairobi:20250604T190000 DTEND;TZID=Africa/Nairobi:20250604T203000 DTSTAMP:20260424T204507 CREATED:20251223T205510Z LAST-MODIFIED:20251223T205705Z UID:40817-1749063600-1749069000@kesho-kenya.org SUMMARY:Cancer Survivorship DESCRIPTION: URL:https://kesho-kenya.org/event/cancer-survivorship/ CATEGORIES:CME 2026,Continuing Medical Education (CME) END:VEVENT BEGIN:VEVENT DTSTART;TZID=Africa/Nairobi:20250528T190000 DTEND;TZID=Africa/Nairobi:20250528T203000 DTSTAMP:20260424T204507 CREATED:20251223T205348Z LAST-MODIFIED:20251223T205348Z UID:40815-1748458800-1748464200@kesho-kenya.org SUMMARY:Brain Cancer / Brain Tumour DESCRIPTION: URL:https://kesho-kenya.org/event/brain-cancer-brain-tumour/ CATEGORIES:CME 2026,Continuing Medical Education (CME) END:VEVENT BEGIN:VEVENT DTSTART;TZID=Africa/Nairobi:20250514T190000 DTEND;TZID=Africa/Nairobi:20250514T203000 DTSTAMP:20260424T204507 CREATED:20251223T205123Z LAST-MODIFIED:20251223T205123Z UID:40811-1747249200-1747254600@kesho-kenya.org SUMMARY:Melanoma/Skin Cancer DESCRIPTION: URL:https://kesho-kenya.org/event/melanoma-skin-cancer/ CATEGORIES:CME 2026,Continuing Medical Education (CME) END:VEVENT BEGIN:VEVENT DTSTART;TZID=Africa/Nairobi:20250430T190000 DTEND;TZID=Africa/Nairobi:20250430T203000 DTSTAMP:20260424T204507 CREATED:20251223T204854Z LAST-MODIFIED:20251223T204854Z UID:40807-1746039600-1746045000@kesho-kenya.org SUMMARY:Testicular Cancer DESCRIPTION: URL:https://kesho-kenya.org/event/testicular-cancer-2/ CATEGORIES:CME 2026,Continuing Medical Education (CME) END:VEVENT BEGIN:VEVENT DTSTART;TZID=Africa/Nairobi:20250423T190000 DTEND;TZID=Africa/Nairobi:20250423T203000 DTSTAMP:20260424T204507 CREATED:20251223T204641Z LAST-MODIFIED:20251223T204641Z UID:40805-1745434800-1745440200@kesho-kenya.org SUMMARY:World AML Day (21st) DESCRIPTION: URL:https://kesho-kenya.org/event/world-aml-day-21st/ CATEGORIES:CME 2026,Continuing Medical Education (CME) END:VEVENT BEGIN:VEVENT DTSTART;TZID=Africa/Nairobi:20250421T190000 DTEND;TZID=Africa/Nairobi:20250421T203000 DTSTAMP:20260424T204507 CREATED:20251223T205238Z LAST-MODIFIED:20251223T210251Z UID:40813-1745262000-1745267400@kesho-kenya.org SUMMARY:Bladder Cancer DESCRIPTION: URL:https://kesho-kenya.org/event/bladder-cancer-2/ CATEGORIES:CME 2026,Continuing Medical Education (CME) END:VEVENT BEGIN:VEVENT DTSTART;TZID=Africa/Nairobi:20250416T190000 DTEND;TZID=Africa/Nairobi:20250416T203000 DTSTAMP:20260424T204507 CREATED:20251223T204430Z LAST-MODIFIED:20251223T204430Z UID:40803-1744830000-1744835400@kesho-kenya.org SUMMARY:Head & Neck Cancer DESCRIPTION: URL:https://kesho-kenya.org/event/head-neck-cancer/ CATEGORIES:CME 2026,Continuing Medical Education (CME) END:VEVENT BEGIN:VEVENT DTSTART;TZID=Africa/Nairobi:20250409T190000 DTEND;TZID=Africa/Nairobi:20250409T203000 DTSTAMP:20260424T204507 CREATED:20251223T204319Z LAST-MODIFIED:20251223T204319Z UID:40801-1744225200-1744230600@kesho-kenya.org SUMMARY:Esophageal Cancer DESCRIPTION: URL:https://kesho-kenya.org/event/esophageal-cancer-3/ CATEGORIES:CME 2026,Continuing Medical Education (CME) END:VEVENT BEGIN:VEVENT DTSTART;TZID=Africa/Nairobi:20250402T190000 DTEND;TZID=Africa/Nairobi:20250402T203000 DTSTAMP:20260424T204507 CREATED:20251223T204154Z LAST-MODIFIED:20251223T204154Z UID:40798-1743620400-1743625800@kesho-kenya.org SUMMARY:Bowel Cancer DESCRIPTION: URL:https://kesho-kenya.org/event/bowel-cancer/ CATEGORIES:CME 2026,Continuing Medical Education (CME) END:VEVENT BEGIN:VEVENT DTSTART;TZID=Africa/Nairobi:20250326T190000 DTEND;TZID=Africa/Nairobi:20250326T203000 DTSTAMP:20260424T204507 CREATED:20251222T172322Z LAST-MODIFIED:20251223T152905Z UID:40769-1743015600-1743021000@kesho-kenya.org SUMMARY:International Women’s Day Women in Oncology DESCRIPTION: URL:https://kesho-kenya.org/event/international-womens-day-women-in-oncology/ CATEGORIES:CME 2026,Continuing Medical Education (CME) END:VEVENT BEGIN:VEVENT DTSTART;TZID=Africa/Nairobi:20250326T190000 DTEND;TZID=Africa/Nairobi:20250326T203000 DTSTAMP:20260424T204507 CREATED:20251223T204036Z LAST-MODIFIED:20251223T210322Z UID:40796-1743015600-1743021000@kesho-kenya.org SUMMARY:Colorectal Cancer DESCRIPTION: URL:https://kesho-kenya.org/event/colorectal-cancer-2/ CATEGORIES:CME 2026,Continuing Medical Education (CME) END:VEVENT BEGIN:VEVENT DTSTART;TZID=Africa/Nairobi:20250313T190000 DTEND;TZID=Africa/Nairobi:20250314T203000 DTSTAMP:20260424T204507 CREATED:20251222T171550Z LAST-MODIFIED:20251223T152912Z UID:40767-1741892400-1741984200@kesho-kenya.org SUMMARY:WoCa Summit EA DESCRIPTION: URL:https://kesho-kenya.org/event/woca-summit-ea/ CATEGORIES:CME 2026,Continuing Medical Education (CME) END:VEVENT BEGIN:VEVENT DTSTART;TZID=Africa/Nairobi:20250305T190000 DTEND;TZID=Africa/Nairobi:20250305T203000 DTSTAMP:20260424T204507 CREATED:20251222T171137Z LAST-MODIFIED:20251223T152927Z UID:40763-1741201200-1741206600@kesho-kenya.org SUMMARY:Kidney Cancer DESCRIPTION: URL:https://kesho-kenya.org/event/kidney-cancer-2/ CATEGORIES:CME 2026,Continuing Medical Education (CME) END:VEVENT BEGIN:VEVENT DTSTART;TZID=Africa/Nairobi:20250219T190000 DTEND;TZID=Africa/Nairobi:20250219T203000 DTSTAMP:20260424T204507 CREATED:20251222T170110Z LAST-MODIFIED:20251223T152934Z UID:40761-1739991600-1739997000@kesho-kenya.org SUMMARY:Gallbladder & Bile Duct Cancer Awareness DESCRIPTION: URL:https://kesho-kenya.org/event/gallbladder-bile-duct-cancer-awareness/ CATEGORIES:CME 2026,Continuing Medical Education (CME) END:VEVENT BEGIN:VEVENT DTSTART;TZID=Africa/Nairobi:20250205T190000 DTEND;TZID=Africa/Nairobi:20250205T203000 DTSTAMP:20260424T204507 CREATED:20251222T165950Z LAST-MODIFIED:20251223T153047Z UID:40757-1738782000-1738787400@kesho-kenya.org SUMMARY:World Cancer Day Building a Resilient Oncology Workforce: Addressing Capacity Gaps in Cancer Management in Kenya DESCRIPTION: URL:https://kesho-kenya.org/event/world-cancer-day-building-a-resilient-oncology-workforce-addressing-capacity-gaps-in-cancer-management-in-kenya/ CATEGORIES:CME 2026,Continuing Medical Education (CME) END:VEVENT END:VCALENDAR